12 WiSys Technologies in "Pharmaceuticals & Vitamin D" or "Food & Supplements" or "Engineering" or "Diagnostic Assays"
WiSys is seeking a strategic partner skilled in the processes of metal treating and finishing who could provide a route to market for the commercialization and use of this anodizing pen.
WiSys is seeking a strategic partner interested in providing a route to market for the commercialization and use of this anthocyanin extraction system. There is also interest in partnering with a fruit processing company for the continued testing and scaling of this system.
WiSys is seeking a strategic partner skilled in the design, modeling, and fabrication of Quantum Dots and Quantum wires. There is interest in working with a partner to test the beta version of the CAE simulation tool and provide feedback when modeling both Quantum Wires and Quantum Dots. Additionally, there is interest in identifying a partner with a 3D finite element method solver for further development and testing of the CAE simulation tool.
WiSys is currently seeking strategic partners operating in the non-destructive testing industry interested in further developing this novel health monitoring system for concrete structures, ultimately providing a route to market for its commercialization.
WiSys is seeking a strategic partner skilled in the development and manufacturing of membranes used for the separation and/or detection of biologic molecules in solution. There is additional interest in a partner with the expertise to identify and test novel applications for these nanomembranes.
WiSys Technology Foundation is currently seeking a strategic industry partner to assist in the further development of its lead compound, A11, and related analogues providing a route to market for their use as novel skin whitening/lightening agents.The competitive advantage of these compounds over existing agents on the market is that they produce long-acting and reversible skin lightening with no toxicity.
The WiSys Technology Foundation is seeking commercial partners interested in developing anxiolytic and anticonvulsant benzodiazepines that offer little or no side effects.